Moreover, GFAP, NF-L, and p-tau181 were significantly associated with disease progression in both biofluids, suggesting that a standardized plasma panel could support early diagnosis, staging, and monitoring of AD progression, even in preclinical stages [202]. Here, GFAP is linked to Alzheimer disease.